Intranasal sumatriptan: in adolescents with migraine.

Abstract

Sumatriptan, a serotonin 5-HT(1B/1D) agonist, constricts cranial blood vessels and inhibits neuroinflammatory processes. A single dose of sumatriptan 10 mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20 mg (at 1 and 2 hours) and 5 mg (at 2 hours) than placebo (pooled data from two studies). Sustained headache relief (1-24 and 2-24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies). Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo [Chart: see text].

• Authors: Monique P Curran, Hannah C Evans, Antona J Wagstaff
• Journal: CNS drugs (CNS Drugs) Vol. 19 Issue 4 Pg. 335-43; discussion 345-6 ( 2005) ISSN: 1172-7047 [Print] New Zealand
• PMID: 15813647 (Publication Type: Journal Article, Review)

Chemical References

• Sumatriptan

Topics

• Administration, Intranasal
• Adolescent
• Humans
• Migraine Disorders (drug therapy, metabolism, physiopathology)
• Sumatriptan (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)